Latest Biotech News

Eli Lilly agreed to acquire 4E Therapeutics to broaden its pain pipeline with an MNK inhibitor approach designed to avoid the opioid pathway. The Austin-based biotech’s lead candidate, 4ET1103, is...

A renewed debate has surfaced around the FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot, with experts urging a pause or reconsideration of the program’s details. Stakeholders...

Biogen is acquiring RayThera in a deal valued at up to $1 billion to add small-molecule immunology assets to its pipeline. The companies said Biogen will provide an undisclosed upfront payment,...

A systematic review and meta-analysis estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody therapy in adult patients with B-cell...

Prime Medicine cleared its Prime Editor program for clinical testing in Wilson’s disease after receiving clearance from Medsafe, New Zealand’s medicines regulator. The company’s investigational...

Memento Medicines launched with a $93 million Series A financing and a licensed lead program aimed at retinal diseases. The company’s start emphasizes ophthalmology as an initial focus area and...

The Global Fund and partners began rollout of 5,000 PlusLife MiniDock Ultra near point-of-care TB test systems across 13 countries supported by $50 million from the Children’s Investment Fund...

Confo Therapeutics presented preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist being developed for life-threatening post-bariatric hypoglycemia...

Germany’s DZNE launched NeuroGenomeHub, a new brain genomics initiative funded with about €6 million to build a global genome database for neurodegenerative diseases. The project aims to sequence...

Eli Lilly agreed to acquire 4E Therapeutics, extending its push for non-opioid pain therapies at a time when the medical community remains focused on alternatives to opioid-based treatment. The...

The FDA granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes rapid molecular group A strep test, giving clinicians a faster point-of-care option for acute pharyngitis. Diasorin...

Biogen moved to strengthen its immunology pipeline by acquiring RayThera in a deal valued at up to $1 billion. The acquisition adds multiple anti-inflammatory small-molecule assets to Biogen’s...

A systematic review and meta-analysis estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody therapy in adults with non-Hodgkin lymphoma and...

Germany’s DZNE launched NeuroGenomeHub, a brain genomics initiative funded with about €6 million to build a global genome database for neurodegenerative diseases. DZNE said the project will...

Prime Medicine received clearance from New Zealand’s Medsafe for the clinical trial application of PM-577a, an investigational Prime Editor for Wilson’s disease. The clearance advances the program...

Oxford Nanopore said Norway’s MATRIX program began rolling out rapid nanopore sequencing for central nervous system tumor classification across the country’s public healthcare infrastructure. The...

Memento Medicines launched with a $93 million Series A financing and secured licensing of a lead program for retinal diseases. The new ophthalmology-focused company is positioned to convert...

Sophia Genetics closed an upsized underwritten public offering after strong investor demand, generating total gross proceeds of $57.5 million before underwriting discounts and commissions. The...

The Global Fund and partners began rolling out PlusLife MiniDock Ultra systems across 13 countries with $50 million in coordinated funding drawn from the Children’s Investment Fund Foundation. The...

Biogen moved to deepen its immunology pipeline by agreeing to acquire RayThera for up to $1 billion, adding early-stage small-molecule anti-inflammatory candidates alongside a lead asset expected...